The Latest Breaking News from Teleflex

Due to Teleflex’s underperformance relative to its industry peers over the past six months, Wall Street analysts remain cautious about the stock’s prospects.

Teleflex has continued to underperform the broader market over the past several years, yet analysts remain moderately bullish on the stock’s prospects.

Despite Teleflex’s underperformance relative to the Dow Jones over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Although Teleflex has lagged behind the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

MINNEAPOLIS — Medtronic is weighing its next steps after losing another round in a long-running patent dispute with med-tech competitor Teleflex Inc.

Teleflex Inc (NYSE: TFX) hosted its Investor Day and issued plans for 2023-2025. RBC Capital Markets believe TFX is a stronger company delivering stable revenue growth in the M-HSDs, margin expansion, double-digit EPS growth, and strong FCF. 

Over the past 3 months, 12 analysts have published their opinion on Teleflex (NYSE:TFX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Despite the prevailing bearish investor sentiment, the healthcare industry is expected to continue growing amid an increase in global chronic diseases, rapid medical advancements, and an aging population. The stocks of quality healthcare companies Bausch Health (BHC), Teleflex (TFX), Abcam (ABCM), and Integra LifeSciences (IART) are currently trading near their…

Upgrades